The Netflix Model for Medicines: How Delinked Subscription Payment Works

Delinked payment means a health system pays a company a fixed sum for access to a medicine instead of paying per unit dispensed. The revenue is separated, or delinked, from the volume prescribed. The United Kingdom applies this to new antibiotics through the Antimicrobial Products Subscription Model, often called the Netflix model because the payer buys unlimited access for a flat annual fee. NHS England pays a set yearly subscription for a qualifying antibiotic whether it treats ten patients or ten thousand, so the manufacturer earns a predictable return while clinicians remain free to hold the drug in reserve. According to NICE and the House of Commons Library, the UK made this the world's first permanent model of its kind in 2024.

The market failure delinkage is designed to fix

Most medicines are paid for by the unit. The more a drug is prescribed, the more its maker earns. For nearly every therapeutic area that alignment is unremarkable. For antibiotics it is a problem.

A genuinely novel antibiotic that overcomes resistant bacteria is most valuable when it is used least. Good stewardship means holding a new agent back as a last-line option so that resistance to it emerges slowly. That is sound clinical policy, and it is also a commercial trap. A company that spends years developing a drug the health system then deliberately keeps on the shelf cannot recover its investment through sales volume. The House of Commons Library describes the consequence bluntly. Several firms that brought new antibiotics to market went bankrupt or exited the field, and the pipeline of new antimicrobials has thinned even as drug-resistant infections rise.

This is a classic example of the difference between what economists call a push incentive and a pull incentive. Push incentives, such as research grants, lower the cost of developing a drug. Pull incentives reward a product once it exists, signalling to industry that the work will pay off. Delinkage is a pull incentive. It promises a return for having a valuable antibiotic available, not for selling large quantities of it.

How the UK subscription model works

The mechanics have two parts. First comes an assessment of value, then a fixed payment based on that value.

NICE runs the evaluation. As NICE describes on its own site, it was commissioned by NHS England to convene an expert panel that assesses each antimicrobial against defined criteria, judging its value to the whole health and care system rather than to an individual patient encounter. That assessment places a product into one of four value bands. According to NHS England's guidance on commercial arrangements, the bands carry fixed annual subscription fees for England ranging from 5 million pounds for an important new antimicrobial up to 20 million pounds for a breakthrough one, with intermediate bands at 10 million and 15 million pounds.

Once a band is set, NHS England pays that flat fee each year for access, and the payment does not move with prescription counts. Contracts run for an initial period with options to extend across a product's exclusivity window. Because the money is fixed, the manufacturer has no reason to encourage wider use, and the health system faces no per-dose pressure that would discourage careful stewardship. The incentive to oversell and the incentive to overuse are both removed at the same time.

The programme began as a pilot. NHS England awarded the first two subscription-style contracts in July 2022, for cefiderocol and for ceftazidime with avibactam, each initially at a fixed fee reported at around 10 million pounds a year. Following public consultation, the government approved the transition from pilot to a permanent model on 8 May 2024. NHS England has since described an expanded scheme covering all four UK nations, with a substantially larger annual budget for new contracts and a fresh round of NICE-led evaluations, and with new contracts anticipated from 2026. Readers should treat forward-looking figures as the published plan rather than settled history, since procurement rounds and budgets are updated over time.

The one-time precedent in hepatitis C

Delinkage is most associated with antibiotics, but the UK used a related idea once before, for a very different reason. In 2019 NHS England struck a deal with the makers of direct-acting antiviral cures for hepatitis C. Here the goal was not to restrain use but to expand it dramatically toward eliminating the infection as a public health problem.

The logic still turned on breaking the link between price and volume. As NHS England announced, the arrangement secured the new hepatitis C drugs at agreed prices, giving the system budget certainty to find and treat as many undiagnosed patients as possible without each additional cure adding unpredictable cost. Hepatitis C differs from the antibiotic case in a crucial way. These antivirals cure the disease, so treating more people shrinks the future patient pool rather than breeding resistance. Delinkage suited both situations, but for opposite ends. Antibiotics call for restraint, while hepatitis C called for a push to treat everyone.

What delinkage does and does not solve

Delinkage is a payment reform, and its reach is limited to the problem it targets. It can restore a business case for keeping valuable antibiotics available and can align payment with stewardship. It does not by itself create new science, guarantee that any given drug reaches the market, or resolve how much a health system should pay in total.

Several judgement calls remain contested. Setting the value of an antibiotic that is deliberately barely used is inherently difficult, and reasonable analysts disagree on whether the UK bands are large enough to move global research decisions. There is also an open question about scale. A national subscription in one country is a modest fraction of what a worldwide pull incentive would need to be, and coordinated international action has proved hard to arrange. These are trade-offs to weigh, not verdicts to render.

What the UK model demonstrates is that a payer can pay for readiness rather than consumption, and can do so through a transparent, criteria-based process. Whether that proves sufficient to refill the antibiotic pipeline is a question the coming years, and the wider international response, will answer.

This article is educational and is not medical advice.